Within the consumer discretionary sector, shares of McGraw-Hill fell as the company reported lower second-quarter profit, partly hurt by a restructuring charge related to job cuts. The company publishes textbooks and owns BusinessWeek magazine and Standard & Poor’s. Its profits report beat Wall Street expectations. But a ruling that Standard & Poor’s must face fraud charges over certain security ratings pressured the company’s share price and the publisher lowered the high end of its full-year adjusted profit guidance. The Fund’s position in H&R Block delivered positive returns for the period but underperformed broadcasters, publishers and other media companies that rebounded from multiple quarters of declines. The tax preparation company reported a quarterly loss in the period but affirmed forecasts for profits for the year.
Signs of a nascent economic recovery and an upturn in demand served to boost share prices for companies in the industrials sector, which had been extremely hard hit by recession. The Fund’s position in refuse hauler Waste Management contributed to gains for the period but underperformed some of the sector’s leaders in commercial printing, defense contracting and transportation. The Fund’s position in Fluor Corp declined as the engineering firm experienced a slowdown in U.S. construction projects. Fluor builds large, complex industrial and infrastructure projects. Despite some volatility it has remained profitable throughout the recession and reported positive quarterly earnings during the period.
In health care, shares of McKesson Corporation rose as the supplier of information and care management products and services company reported better-than-expected quarterly profits. The pharmaceuticals wholesaler noted that strong cash flow and cost management enabled it to raise its full-year earnings forecast, which helped send share prices higher. Shares of Shire Pharmaceuticals also advanced on a positive quarterly earnings report. The company is in talks with the Food and Drug Administration about bringing a drug for a rare disease to U.S. patients, as rival Genzyme Corp. faces shortages for its best-selling treatments. The Shire drugs are alternatives to treatments made by Genzyme, which is having trouble supplying the drugs since its Boston manufacturing plant was shut down in June following a viral contamination.
Gains in the Fund’s technology holdings reflected improved consumer confidence. Communications and information technology company Harris Corp. reported earnings results that topped Wall Street expectations and the company offered a strong forecast, sending the stock up for the period. The company cited new contract wins, improved order rates, and a solid pipeline of new opportunities. CA Inc also posted earnings results that beat Wall Street's expectations and the business-software maker raised its fiscal-year forecast.
|